# Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT

> **NCT02735317** · PHASE2 · UNKNOWN · sponsor: **Yun-fei Xia** · enrollment: 90 (estimated)

## Conditions studied

- Nasopharyngeal Neoplasms
- Stomatitis

## Interventions

- **DRUG:** Oral Ulcer Gargle (FORRAD®)
- **DRUG:** Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine

## Key facts

- **NCT ID:** NCT02735317
- **Lead sponsor:** Yun-fei Xia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2016-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02735317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02735317, "Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02735317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*